Replies to post #243804 on Biotech Values

[DewDiligence]

Yes, it’s noteworthy that CLVS did not disclose the HRD-negative (HRp) data in the ESMO PR; however, we know that in CLVS’ Mar 2022 update, the PFS HR for the HRD-negative (HRp) subgroup was 0.65 (95% CI: 0.45-0.95).

https://www.businesswire.com/news/home/20220331005384/en/Clovis-Oncology%E2%80%99s-Rubraca%C2%AE-Rucaparib-Significantly-Improves-Progression-Free-Survival-in-First-line-Maintenance-Treatment-in-Women-with-Ovarian-Cancer-Regardless-of-Their-Biomarker-Status-in-Phase-3-ATHENA-MONO-Trial